Proteasome inhibition and its therapeutic potential in multiple myeloma

Ajai Chari1, Amitabha Mazumder2, Sundar Jagannath11Mount Sinai School of Medicine, New York, NY, USA; 2New York University School of Medicine, New York, NY, USAAbstract: Due to an unmet clinical need for treatment, the first in class proteasome inhibitor, bortezomib, moved from drug discovery to FDA...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Ajai Chari, Amitabha Mazumder, Sundar Jagannath
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2010
Materias:	Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/bfa5dae794bc4d58b562ef9039d50e04
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:bfa5dae794bc4d58b562ef9039d50e04
record_format	dspace
spelling	oai:doaj.org-article:bfa5dae794bc4d58b562ef9039d50e042021-12-02T00:36:42ZProteasome inhibition and its therapeutic potential in multiple myeloma1177-54751177-5491https://doaj.org/article/bfa5dae794bc4d58b562ef9039d50e042010-09-01T00:00:00Zhttp://www.dovepress.com/proteasome-inhibition-and-its-therapeutic-potential-in-multiple-myelom-a5371https://doaj.org/toc/1177-5475https://doaj.org/toc/1177-5491Ajai Chari1, Amitabha Mazumder2, Sundar Jagannath11Mount Sinai School of Medicine, New York, NY, USA; 2New York University School of Medicine, New York, NY, USAAbstract: Due to an unmet clinical need for treatment, the first in class proteasome inhibitor, bortezomib, moved from drug discovery to FDA approval in multiple myeloma in an unprecedented eight years. In the wake of this rapid approval arose a large number of questions about its mechanism of action and toxicity as well as its ultimate role in the treatment of this disease. In this article, we briefly review the preclinical and clinical development of the drug as the underpinning for a systematic review of the large number of clinical trials that are beginning to shed some light on the full therapeutic potential of bortezomib in myeloma. We conclude with our current understanding of the mechanism of action of this agent and a discussion of the novel proteasome inhibitors under development, as it will be progress in these areas that will ultimately determine the true potential of proteasome inhibition in myeloma.Keywords: bortezomib, multiple myeloma Ajai ChariAmitabha MazumderSundar JagannathDove Medical PressarticleMedicine (General)R5-920ENBiologics: Targets & Therapy, Vol 2010, Iss default, Pp 273-287 (2010)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine (General) R5-920
spellingShingle	Medicine (General) R5-920 Ajai Chari Amitabha Mazumder Sundar Jagannath Proteasome inhibition and its therapeutic potential in multiple myeloma
description	Ajai Chari1, Amitabha Mazumder2, Sundar Jagannath11Mount Sinai School of Medicine, New York, NY, USA; 2New York University School of Medicine, New York, NY, USAAbstract: Due to an unmet clinical need for treatment, the first in class proteasome inhibitor, bortezomib, moved from drug discovery to FDA approval in multiple myeloma in an unprecedented eight years. In the wake of this rapid approval arose a large number of questions about its mechanism of action and toxicity as well as its ultimate role in the treatment of this disease. In this article, we briefly review the preclinical and clinical development of the drug as the underpinning for a systematic review of the large number of clinical trials that are beginning to shed some light on the full therapeutic potential of bortezomib in myeloma. We conclude with our current understanding of the mechanism of action of this agent and a discussion of the novel proteasome inhibitors under development, as it will be progress in these areas that will ultimately determine the true potential of proteasome inhibition in myeloma.Keywords: bortezomib, multiple myeloma
format	article
author	Ajai Chari Amitabha Mazumder Sundar Jagannath
author_facet	Ajai Chari Amitabha Mazumder Sundar Jagannath
author_sort	Ajai Chari
title	Proteasome inhibition and its therapeutic potential in multiple myeloma
title_short	Proteasome inhibition and its therapeutic potential in multiple myeloma
title_full	Proteasome inhibition and its therapeutic potential in multiple myeloma
title_fullStr	Proteasome inhibition and its therapeutic potential in multiple myeloma
title_full_unstemmed	Proteasome inhibition and its therapeutic potential in multiple myeloma
title_sort	proteasome inhibition and its therapeutic potential in multiple myeloma
publisher	Dove Medical Press
publishDate	2010
url	https://doaj.org/article/bfa5dae794bc4d58b562ef9039d50e04
work_keys_str_mv	AT ajaichari proteasomeinhibitionanditstherapeuticpotentialinmultiplemyeloma AT amitabhamazumder proteasomeinhibitionanditstherapeuticpotentialinmultiplemyeloma AT sundarjagannath proteasomeinhibitionanditstherapeuticpotentialinmultiplemyeloma
_version_	1718403644289712128

Proteasome inhibition and its therapeutic potential in multiple myeloma

Ejemplares similares